



COVID-19 (SARS-CoV-2) Pandemic Impact on Hematopoietic Cell Transplantation (HCT)

Audience: U.S. Data Managers and Medical Directors

REMINDER: Supplemental Data Collection Request

Effective, **August 25, 2020**, in an effort to determine the impact of the COVID-19 pandemic on autologous and allogeneic hematopoietic cell transplantation practice, including outcomes, CIBMTR is requesting supplemental data for each qualifying transplant registered. This includes all allogeneic HCTs and research consented autologous HCTs. These data are essential to understanding how changes to the original transplant plan affect recipient outcomes. Impacts include changes to the original HCT date, donor, product type, preparative regimen, GVHD prophylaxis, and the need to cryopreserve the product. These data are expected to be used in future studies and reports, including the annual Center-Specific Survival Analysis (CSA) for HCT. The supplemental data will be collected prospectively, as long as the pandemic impacts how HCTs are performed. We are committed to ending the supplemental data collection at that time.

Please refer to the memo [here](#) for additional information regarding the next steps for this data collection.

Richter's Transformation

Audience: U.S. and International Data Managers

CIBMTR Reporting Reminder

After a chronic lymphocytic leukemia (CLL) diagnosis, a histologic transformation may occur. When CLL transforms into diffuse large B-cell lymphoma, this is known as a Richter's transformation or Richter's syndrome. In these cases, the primary disease for transplant to report on the Disease Classification (2402 R5) Form is non-hodgkin lymphoma (NHL), and the transformation will be captured in Q383. Only the NHL section will need to be completed (not the Other Leukemia (OL) section).

Form / Instruction Manual Update

In the Other Leukemia section for the "Yes" option in Q376, incorrect text stating to also complete the NHL section has been removed, as the Other Leukemia section will never be completed in the case of Richter's transformation, only the NHL section. The Forms Instruction Manual has also been updated for clarification.

Other Leukemia (OL)

373. Specify the other leukemia classification

- Chronic lymphocytic leukemia (CLL), NOS (34) - **Go to question 375**
- Chronic lymphocytic leukemia (CLL), B-cell / small lymphocytic lymphoma (SLL) (71) - **Go to question 375**
- Hairy cell leukemia (35) - **Go to question 378**
- Hairy cell leukemia variant (75) - **Go to question 378**
- Monoclonal B-cell lymphocytosis (76) - **Go to signature line**
- Prolymphocytic leukemia (PLL), NOS (37) - **Go to question 375**
- PLL, B-cell (73) - **Go to question 375**
- PLL, T-cell (74) - **Go to question 375**
- Other leukemia, NOS (30) - **Go to question 377**
- Other leukemia (39) - **Go to question 374**

374. Specify other leukemia: _____ - **Go to question 377**

375. Was any 17p abnormality detected?

- Yes - **If disease classification is CLL, go to question 376. If PLL, go to question 378.**
- No

376. Did a histologic transformation to diffuse large B-cell lymphoma (Richter syndrome) occur at any time after CLL diagnosis?

- Yes - **Go to question 380 - Also complete NHL Disease Classification questions** 
- No - **Go to question 378**

CIBMTR Forms Instruction Manual

Audience: U.S. and International Data Managers

Forms Instruction Manual Updates

The following sections of the Forms Instruction Manual have been updated this past week.

- Pre-TED (2400)
- Disease Classification (2402)
- Post-TED (2450)
- Post-HCT Follow-Up (2100)
- MDS Response Criteria
- MPN Response Criteria
- MDS Pre-Infusion (2014)
- MDS Post-Infusion (2114)
- MPN Post-Infusion (2157)

For an overview of the updates, review the Manual Updates table at the bottom of the [Getting Started](#) page. Please contact the [CIBMTR Customer Support](#) if there are any questions.